European Commission approves TREMFYA ® (guselkumab) for the treatment of active psoriasis arthritis (PsA)

Johnson and Johnson Pharmaceuticals announced today that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adult patients with active psoriasis arthritis (PsA), who are not responsive or insufficiable to previous treatments for anti-disease rheumatoid drugs (DMARD).
Guselkumab is the first approved all-human monoclonal antibody that selectively binds to the p19 sub-base of erythrogen (IL)-23 and inhibits its interaction with the IL-23 receptor.
has been approved for the treatment of patients with moderate to severe psoriasis.
IL-23 is an important driver of the progression of inflammatory diseases, including psoriasis and PSA.
PsA is a chronic immune-mediated inflammatory disease characterized by joint damage and inflammation in addition to enteritis, mastitis, axon disease and skin lesions associated with psoriasis.
, stiffness and swelling of the joints and connective tissue can be severe and make daily work difficult.
there is no cure for PSA, and it is estimated that one-third of Europe's 14 million psoriasis patients will continue to develop PSA.
。